Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FLNA
STRONG SELLREMOVEFilana Therapeutics, Inc. · Healthcare · United States · $75M · Avg Vol: $453K/d
Filana Therapeutics is a micro-cap biotech with high cash burn and no validated clinical platform, failing our quality and margin of safety requirements.
COMPANY DESCRIPTION
Filana Therapeutics, Inc. is a biotechnology firm dedicated to developing novel small-molecule therapeutics for neurodegenerative and metabolic disorders. The company's competitive moat is built upon its proprietary drug discovery platform that targets cellular stress pathways. It operates as an early-stage, research-driven biotechnology player aiming to address significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — |
| EPS | — | -1.90 | -2.32 | -0.53 | -1.88 | — |
| Shares | — | 42M | 42M | 48M | 48M | +15.7% |
| Debt | 236,000 | 139,000 | 0 | 12M | 44M | 269.4% |
| Equity | — | 228M | 137M | 146M | 74M | -31.1% |
| Op CF | — | -78M | -82M | -117M | -32M | — |
| Inv CF | — | -3M | -414,000 | -103,000 | -581,000 | — |
| Fin CF | — | 48M | 3M | 124M | -239,000 | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FLNA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FLNA | Filana Therapeutics, Inc.(you) | $75M | 11 | STRONG SELL |
| GOSS | Gossamer Bio, Inc. | $79M | 9 | STRONG SELL |
| 2257.HK | Sirnaomics Ltd. | $82M | 7 | STRONG SELL |
| ACRV | Acrivon Therapeutics, Inc. | $70M | 14 | STRONG SELL |
| BMEA | Biomea Fusion, Inc. | $100M | 10 | STRONG SELL |
| ANIX | Anixa Biosciences, Inc. | $91M | 7 | STRONG SELL |
| AARD | Aardvark Therapeutics, Inc. | $92M | 7 | STRONG SELL |
| PTHS | Pelthos Therapeutics Inc. | $90M | 15 | STRONG SELL |
| COYA | Coya Therapeutics, Inc. | $113M | 11 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $107M | 9 | STRONG SELL |
Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%